Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study.

van Roekel, CarenPoukka, EeroTurunen, TopiNohynek, HannaPresser, LanceMeijer, AdamHeikkinen, TerhoKramer, RolfBegier, ElizabethTeirlinck, Anne CKnol, Mirjam J2024-03-082024-03-082023-11-033793504610.1093/infdis/jiad483http://hdl.handle.net/10029/627365en© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.(severe) acute respiratory infectionRSVmonoclonal antibodyreal-world effectivenesstest-negative design studyvaccineEffectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study.Article1537-6613J Infect Dis 2024;229(Supplement_1):S92-S99